This effect was not restricted to Venetoclax, as knockout or pharmacologic inhibition of ABCC1 also sensitized AML cells to other BH3 mimetics, including ABT-737, Navitoclax and the novel BCL-2/BCL-xL inhibitor AZD-4320. This evidence concerns the gene BCL2 and acute myeloid leukemia.